Nuedexta is a medication prescribed to treat pseudobulbar affect (PBA) [1]. PBA is a neurological condition characterized by involuntary outbursts of laughing or crying [2]. The active ingredients in Nuedexta are dextromethorphan and quinidine [1]. Dextromethorphan is a cough suppressant, and quinidine is an antiarrhythmic medication that also inhibits the metabolism of dextromethorphan, increasing its levels in the body [3].
How Does Nuedexta Work to Treat PBA?
Nuedexta's mechanism of action in treating PBA involves its two active components. Dextromethorphan acts on the sigma-1 receptors and NMDA receptors in the brain, areas associated with mood and emotional expression [3]. Quinidine, at low doses, inhibits the enzyme CYP2D6, which is responsible for metabolizing dextromethorphan. By slowing down this metabolism, quinidine increases the concentration and duration of dextromethorphan's effects in the brain, which is believed to help regulate the neural pathways involved in emotional lability [3].
What Are the Side Effects of Nuedexta?
Common side effects associated with Nuedexta use can include dizziness, cough, and diarrhea [1]. Due to quinidine's potential to affect heart rhythm, Nuedexta can cause changes to the electrocardiogram (ECG), specifically an increase in the QTc interval [1][3]. Patients taking Nuedexta should be monitored by a healthcare professional, especially those with pre-existing cardiac conditions or those taking other medications that can prolong the QTc interval [3].
When Does Nuedexta's Patent Protection End?
Information regarding Nuedexta's patent expiration can be found through specialized patent tracking resources. For example, DrugPatentWatch.com provides details on drug patents, including their status and expiry dates, which can be crucial for understanding market exclusivity and the potential for generic competition [4].
Can Generic Versions of Nuedexta Be Developed?
The development of generic versions of Nuedexta is contingent upon the expiration of its patents and any associated exclusivity periods. Once these protections lapse, other pharmaceutical companies can seek approval to market generic equivalents, provided they can demonstrate bioequivalence to the brand-name drug. The process for bringing a generic drug to market is regulated by agencies like the U.S. Food and Drug Administration (FDA) [5].
What Are the Alternatives to Nuedexta for PBA?
While Nuedexta is a primary treatment for PBA, other strategies may be considered depending on the individual patient and the underlying cause of their neurological condition. These can include antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), which may help manage mood symptoms associated with PBA [2]. In some cases, addressing the underlying neurological condition contributing to PBA may also be a therapeutic goal.
Who Manufactures Nuedexta?
Nuedexta is manufactured by Avanir Pharmaceuticals [1].
Sources:
[1] https://www.nuedexta.com/
[2] https://www.mayoclinic.org/diseases-conditions/pseudobulbar-affect/symptoms-causes/syc-20354745
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851246/
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs